BiotechTube

Metformin + Alogliptin + empagliflozin

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

T2DM

Conditions

T2DM, Diabete Type 2, DM

Trial Timeline

Jul 18, 2025 → Apr 1, 2027

NCT ID
NCT07093476

About Metformin + Alogliptin + empagliflozin

Metformin + Alogliptin + empagliflozin is a phase 3 stage product being developed by Celltrion for T2DM. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07093476. Target conditions include T2DM, Diabete Type 2, DM.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07093476Phase 3Recruiting

Competing Products

20 competing products in T2DM

See all competitors
ProductCompanyStageHype Score
MKP10241 + PlaceboMankind PharmaPhase 2
52
CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + MetforminCelltrionPhase 3
77
L03RD1 + L03RD2 + CT-L03CelltrionPhase 1
33
DulaglutideEli LillyPhase 1
33
SHR-3167 + SHR-3167 PlaceboJiangsu Hengrui MedicinePhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tabletsAstraZenecaApproved
85
Dapagliflozin + Metformin XR + GlucophageAstraZenecaPhase 1
33
AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+PlaceboAstraZenecaPhase 1
33
Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mgAstraZenecaPhase 1
33
Comparator: sitagliptin phosphate + Comparator: placebo (unspecified)MerckPhase 1
33
ErtugliflozinMerckPhase 1
33
Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptinMerckPhase 1
33
Sitagliptin phosphate + Comparator: Sulfonylurea + MetforminMerckApproved
85
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day + comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/dayMerckPhase 3
77
Vildagliptin (LAF237) + Placebo + Insulin + MetforminNovartisApproved
85
LIK066 + PlaceboNovartisPhase 1/2
41
Vildagliptin + Metformin + sulfonylurea (SU) + Basal InsulinNovartisPhase 3
77
Maridebart cafraglutide + PlaceboAmgenPhase 3
76
Maridebart Cafraglutide + PlaceboAmgenPhase 2
51

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85